ArticleAnnals of translational medicine2022

Sacituzumab govitecan and other antibody-drug conjugates targeting trophoblast cell-surface antigen 2 (Trop-2) in breast cancer.

Ashley Matusz-Fisher et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.